Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 3/20 | 0.54 |
| ▸ | FNTA | P49354 | 17/20 | 0.49 |
| ▸ | FNTB | P49356 | 17/20 | 0.49 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8227314 | 0.87 | FNTA (0.42) | AGTR2FNTAFNTBPGGT1B | |
| SCHEMBL7248023 | 0.81 | CYP19A1 (0.48) | AGTR2 | |
| SCHEMBL8207053 | 0.81 | FNTA (0.52) | AGTR2FNTAFNTBPGGT1B | |
| SCHEMBL7703271 | 0.78 | FNTA (0.46) | AGTR2FNTAFNTBPGGT1B | |
| SCHEMBL7706109 | 0.78 | FNTA (0.46) | AGTR2FNTAFNTBPGGT1B | |
| SCHEMBL7706112 | 0.78 | FNTA (0.46) | AGTR2FNTAFNTBPGGT1B | |
| SCHEMBL7703276 | 0.78 | FNTA (0.46) | AGTR2FNTAFNTBPGGT1B | |
| SCHEMBL8206537 | 0.78 | FNTA (0.46) | AGTR2FNTAFNTBPGGT1B | |
| SCHEMBL7703349 | 0.77 | FNTA (0.48) | AGTR2FNTAFNTBPGGT1B | |
| SCHEMBL7703353 | 0.77 | FNTA (0.48) | AGTR2FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6414145-B1 | TREATING CANCER AND NEUROFIBROMATOSIS | ZENECA LIMITED (GB) | 2002-07-02 | — | — | US | disclosed |
| EP-0975603-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | ZENECA LIMITED (GB) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998032741-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | ZENECA LIMITED (GB) | 1998-07-30 | — | — | WO | disclosed |